Summary

Eligibility
for people ages 25-35 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Stephen Lazarus, MD
Photo of Stephen Lazarus
Stephen Lazarus

Description

Summary

The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.

Official Title

The American Lung Association (ALA) Lung Health Cohort

Details

The scientific goal of the study is to establish the relationship between a variety of factors (lifetime environmental exposures, fitness and physical activity, biomarkers, nasal respiratory epithelial transcriptome) and ideal versus impaired peak lung health (reserve and markers of susceptibility in investigators' model) in young adulthood. In addition to the initial baseline assessment, remote contacts (e.g., via text message, email, mail, or phone) at regular intervals will allow for both the retention of the participants as well as the collection of additional short-term follow-up information, i.e., within 4.5 years of enrollment. If additional funding becomes available, investigators will extend the study for an additional period of time to study factors related to long-term changes in lung health over time, i.e., at 5 years and beyond.

Keywords

Lung Diseases lung health environmental exposure chest CT spirometry biomarkers

Eligibility

You can join if…

Open to people ages 25-35

1- Age 25-35 years at the time of the baseline examination 2- Able to read and understand English or Spanish 3 -Has a social security number 4- Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination. Note: Individuals who are residents of the US who have temporarily spent time living outside of the US during the last 12 months (e.g., student exchange program, military posting) are eligible for participation.

5- Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant

You CAN'T join if...

  1. Severe asthma, which is defined as any of the following:
  2. Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; Medium dose = >250 fluticasone, propionate =100 fluticasone furoate, >200 beclomethasone, >400 budesonide, >220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS.

OR

  1. 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months OR
  2. One asthma hospitalization in the past 12 months
  3. History of any chronic lung disease other than asthma including but not limited to COPD, cystic fibrosis, pulmonary fibrosis, pulmonary hypertension
  4. Current pregnancy
  5. History of cancer other than non-melanoma skin cancer
  6. Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease)
  7. Inability to comply with study procedures, including
  8. Inability or unwillingness to provide informed consent
  9. Inability to perform study measurements
  10. Inability to be contacted by phone (via calls and/or text messaging) or email
  11. Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit).
  12. Institutionalization

Locations

  • University of California, San Francisco not yet accepting patients
    San Francisco California 94143 United States
  • University of California, Los Angeles not yet accepting patients
    Los Angeles California 90095 United States

Lead Scientist at UCSF

  • Stephen Lazarus, MD
    Professor, Medicine. Authored (or co-authored) 163 research publications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Johns Hopkins University
ID
NCT04543461
Study Type
Observational
Last Updated